# Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients

> **NCT03829462** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Institut du Cancer de Montpellier - Val d'Aurelle** · enrollment: 377 (actual)

## Conditions studied

- Metastatic Colorectal Cancer (mCRC)

## Interventions

- **DRUG:** Regorafenib
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT03829462
- **Lead sponsor:** Institut du Cancer de Montpellier - Val d'Aurelle
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-03-28
- **Primary completion:** 2024-09-04
- **Final completion:** 2026-09
- **Target enrollment:** 377 (ACTUAL)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03829462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03829462, "Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03829462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*